pirtobrutinib – Medxy AI

Pirtobrutinib Matches and May Surpass Ibrutinib in BTKi‑Naïve CLL/SLL: First Randomized Head‑to‑Head Results with Improved Cardiac Safety

By MedXY 12/07/2025

In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hypertension.

$Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia$

Hematology-Oncology news

Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia

By MedXY 10/14/2025

This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynamics and resistance without clear drivers.

Clinical Updates Hematology-Oncology news Specialties

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.